We hold monthly Seminars in Psychedelic Medicine that are open to those who are interested. Please email email@example.com to be added to our email list.
Michael Bogenschutz, MD. April 2023
Title: Exploring mechanisms of psilocybin-assisted treatment for alcohol use disorder.
Description: We will describe the historical and scientific context of current research on psychedelics and review the efficacy data for classic psychedelics in the treatment of substance use disorders. We will discuss what recent preclinical and mechanistic clinical research can tell us about how classic psychedelics may work in the treatment of AUD, and consider possible future directions for research to answer the “burning questions” in the field.
Jordan Sloshower, MD & Patrick D. Skosnik, PhD. February 2023
Title: Psilocybin-Induced Neuroplasticity in the Treatment of Major Depressive Disorder: An Exploratory Placebo-controlled, Fixed-order Trial
Description: Several early phase studies have demonstrated that psilocybin-assisted therapy has rapid-acting and persisting antidepressant effects from just one or two doses. However, methodological limitations (e.g., placebo-control, blinding) limit interpretability of the existing literature and mechanisms of action remain unclear. This talk presented the methods and results of an exploratory placebo-controlled, fixed order study of psilocybin-assisted therapy among individuals with moderate to severe major depression (n=19). The study aimed primarily to investigate the role of neuroplasticity and psychological flexibility as mechanisms of change.
Paul Stamets. January 2023
Title: Psilocybin Mushrooms and their Tryptamines: Potential Medicines for Neurogeneration
Description: The recent upsurge in interest in psilocybin mushrooms by the scientific community is attributable to their long use in history, their widespread use today, and the increasing number of clinical studies validating psilocybin as a breakthrough medicine. What is not yet well elucidated is the efficacy of microdosing and the mechanisms of action for neurogenesis and neurogeneration.
Paul speaks of their historical use and then explores psilocybin's potential for neurological health based on recent results on molecular modes of action which our team has discovered. As co-founder of MycoMedica Life Sciences, PBC (www.mycomedica.com), which has raised $60 million, his team is well positioned for conducting clinical studies based, in part, on the 3 composition patents recently awarded to Paul on his psilocybin discoveries.
Natalie Gukasyan, MD. November 2022
Title: Placebo, expectancy, and psychotherapy effects in psychedelic-assisted therapy
Description: This talk covered the challenges and biases that confound clinical trials with psychedelics, including the challenges of executing placebo-controlled research. It examined how many of these challenges are shared by the broader field of general psychotherapy research, and some of the debate and solutions that have emerged from that body of work. We also discussed the debate around the concept of placebo in interventions that employ psychotherapy. Finally, we reviewed implications of these concepts for future research and potential solutions.
Lucie Berkovitch, MD, PhD. September 2022
Title: Psychedelics in the brain: An overview of neuroimaging studies
Description: This talk provides an exhaustive overview of neuroimaging data on psychedelics. It is divided in three parts: 1) from receptors to brain effects, 2) from brain to cognition, 3) from neurobehavioural effects to theoretical models.
In a first part, we describe psychedelic effects on brain networks, brain oscillations, signal complexity/entropy and on some specific functions such as emotional processing, social processing, surprise processing.
In the second part, we try to predict their cognitive effects based on their brain effects and compare those predictions to actual findings.
In the third part, we summarize existing models to explain psychedelic effects and propose another angle of description of their effects based on the theoretical models of consciousness.
L. A. Paul, PhD. April 2022
Title: Epistemic change and transformation
Description: Certain types of life experiences can be transformative, both epistemically and personally. By transforming you, they change how you think and value, and in the process, they restructure the nature and meaning of your life. L.A. discussed the nature of transformative change, with particular attention to how it involves a distinctive kind of epistemic revision that may be helpful in framing the epistemology of psychedelic experience. L.A. also discussed connections to philosophical issues that arise with informed consent, advance directives, and disability.
Shariful Syed, MD & Deepak Cyril D’Souza, MD. March 2022
Title: Dose-Related Safety, Tolerability, and Efficacy of Dimethyltryptamine (DMT) In Healthy Volunteers and Individuals with Major Depressive Disorder – preliminary findings
Description: Dimethyltryptamine (DMT) is a potent, rapid-onset and short-acting psychedelic drug that has not yet been independently tested for the treatment of depression. The safety, tolerability, and efficacy of intravenous DMT were investigated in treatment-resistant individuals with major depressive disorder (MDD) and healthy controls (HC) in an open-label, fixed-order, dose-escalation (0.1 mg/kg followed by 0.3 mg/kg) study that was conducted in a typical hospital setting with strategic psychoeducation/support, but minimal psychotherapy. Tolerability, safety, cardiovascular function, abuse liability, psychedelic and psychotomimetic effects, mood, and anxiety were assessed at each dosing session. In addition, depression was measured in MDD participants 1 day after each dosing session. Preliminary findings (n=10) were discussed.
Alan Anticevic, PhD. February 2022
Title: Mapping neuro-behavioral heterogeneity of psychedelic neurobiology in humans
Gerard Sanacora, MD, PhD & Sam Wilkinson, MD. December 2021
Title: Regulatory Approval and Implementation of Psychoactive Therapies for Psychiatric Disease: Lessons Learned from Esketamine
Description: The first half of this discussion summarized the key principles and lessons learned from the approval and implementation of esketamine and how we might apply this to future therapies which are administered under strict regulatory control. In the second half, we discussed the findings of a newly reported (top-line results) trial on psilocybin (COMPASS).